GOCOVRI extended-release capsules: February 2026 label

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

GOCOVRI: MDRD method despite a creatinine-clearance heading

The label expressly uses MDRD and indexed units. The immediate-release amantadine record has different product-specific schedules; a numerically similar renal value is not proof of equivalence.

Before applying: Verify renal method and formulation before selecting the nightly extended-release regimen. Do not transfer an immediate-release schedule or dialysis dose.

Also check: GOCOVRI: MDRD method despite a creatinine-clearance heading

Official source

GOCOVRI extended-release capsules: February 2026 label

Product / population: GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.
Renal measure: Table calls the measure creatinine clearance, but expressly specifies MDRD and mL/min/1.73 m2.

RX GOCOVRI retrieval failed; this separate official source does not make that RX attempt successful.

Renal dosing, restrictions and evidence limits

At the source's indexed renal estimate 60-89, start 137 mg nightly and increase after one week to 274 mg nightly. At 30-59, start 68.5 mg nightly; the maximum is 137 mg nightly, with increase if needed after one week. At 15-29, 68.5 mg nightly is both initial and maximum dose. Below 15, treatment is contraindicated. The renal table expressly uses MDRD despite its creatinine-clearance heading. Do not substitute an unindexed Cockcroft-Gault value or an immediate-release amantadine schedule without reconciliation. Do not stop abruptly; follow the label's withdrawal instructions.

Source revision: February 2026 | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bee0631-0028-1314-e063-6394a90aaaed

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

GOCOVRI extended-release capsules: February 2026 label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.

Renal method: Table calls the measure creatinine clearance, but expressly specifies MDRD and mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measure and formulation

GOCOVRI: MDRD method despite a creatinine-clearance heading

The label expressly uses MDRD and indexed units. The immediate-release amantadine record has different product-specific schedules; a numerically similar renal value is not proof of equivalence.

How to use this: Verify renal method and formulation before selecting the nightly extended-release regimen. Do not transfer an immediate-release schedule or dialysis dose.

GOCOVRI extended-release capsules: February 2026 label Amantadine (source heading: Amantidine)

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

GOCOVRI extended-release capsules: February 2026 label

GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.

Method: Table calls the measure creatinine clearance, but expressly specifies MDRD and mL/min/1.73 m2.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope GOCOVRI extended-release capsules: February 2026 label

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bee0631-0028-1314-e063-6394a90aaaed

Exact product and population

GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.

RDM39-SCOPE-amantadine-gocovri-er · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

GOCOVRI extended-release capsules: February 2026 label

Open original reference

Open / share this exact local source

DailyMed / Supernus Pharmaceuticals · GOCOVRI extended-release amantadine capsules for adults with Parkinson-related indications; not immediate-release amantadine.

Renal method: Table calls the measure creatinine clearance, but expressly specifies MDRD and mL/min/1.73 m2.
Source date: February 2026
Retrieved: 2026-09-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM39-official-amantadine-gocovri-er-01b72804c0-C1 · Source locator: Sections 2.3, 2.4, 4 and 8.6

Source-specific limits

RX GOCOVRI retrieval failed; this separate official source does not make that RX attempt successful.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bee0631-0028-1314-e063-6394a90aaaed
Retrieved: 2026-09-07
Exact label title: GOCOVRI extended-release capsules: February 2026 label
DailyMed Set ID: 2bee0631-0028-1314-e063-6394a90aaaed
Labeler: Supernus Pharmaceuticals
Label revision: February 2026
Renal-function method: Table calls the measure creatinine clearance, but expressly specifies MDRD and mL/min/1.73 m2.
Source date/version: February 2026
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 073ddef32e6fccb3334c87e56b522eb8c2059b44ba79d5d12ac378551325aa3e

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bee0631-0028-1314-e063-6394a90aaaed
Source retrieval: 2026-09-07. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: 3cf2d6f5354f9f17814ec4c8993524c6a5b7d45f00a11f09a16539739a3530e1
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report